Dr. Tomás Duraj

Dr. Tomás Duraj, a physician-scientist at Boston College, specializes in cancer metabolism, focusing on glioblastoma treatment. He challenges conventional mutation-focused therapies, arguing for the potential of ketogenic metabolic therapy to exploit cancer's metabolic vulnerabilities. Dr. Duraj introduces the Glucose-Ketone Index as a key biomarker and advocates for protecting healthy cells during treatment. He suggests small pilot studies for better insights, offering a promising view of the future of metabolic oncology.

Dr. Tomás Duraj, a physician-scientist specializing in cancer metabolism, discusses revolutionary insights on targeting cancer through its metabolism. He explains how mitochondrial dysfunction underpins cancer development and explores the Warburg effect, emphasizing the need to target both glucose and glutamine metabolism. Duraj advocates for ketogenic therapy combined with standard treatments to create a hostile environment for tumors. He also highlights innovative imaging techniques and the potential for broader applications of metabolic strategies across various cancer types.

Thomas Seyfried, a mitochondrial metabolic cancer researcher; Derek Lee, who defined mitochondrial substrate-level phosphorylation; and Tomás Duraj, a clinician-scientist translating metabolic oncology into practice. They explore the mitochondrial theory of cancer, ketogenic and glutamine-targeting metabolic therapies, bioelectric and ion-channel links to metabolism, and translational challenges from mice to humans.